Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP3 | Q9NSD7 | 18/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27001816 | 0.95 | RXFP3 (1.00) | RXFP3TMEM97ALDH1A1MAPT | |
| SCHEMBL27001815 | 0.95 | RXFP3 (0.90) | RXFP3TMEM97ALDH1A1NPC1LMNA | |
| SCHEMBL29936897 | 0.92 | RXFP3 (0.86) | RXFP3TMEM97ALDH1A1NPC1LMNA | |
| SCHEMBL27001788 | 0.92 | RXFP3 (0.86) | RXFP3TMEM97ALDH1A1NPC1LMNA | |
| SCHEMBL27001831 | 0.92 | RXFP3 (0.90) | RXFP3TMEM97ALDH1A1NPC1LMNA | |
| SCHEMBL27001824 | 0.91 | RXFP3 (1.00) | RXFP3TMEM97ALDH1A1MAPT | |
| SCHEMBL27001791 | 0.91 | RXFP3 (0.84) | RXFP3TMEM97ALDH1A1NPC1LMNA | |
| SCHEMBL27001827 | 0.91 | RXFP3 (0.84) | RXFP3TMEM97SMN1; SMN2 | |
| SCHEMBL29937169 | 0.91 | RXFP3 (1.00) | RXFP3TMEM97ALDH1A1MAPT | |
| SCHEMBL29936943 | 0.91 | RXFP3 (1.00) | RXFP3TMEM97ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208955-A1 | SMALL MOLECULE ANTAGONISTS FOR THE RELAXIN-3/RXFP3 SYSTEM | RESEARCH TRIANGLE INSTITUTE | 2024-06-27 | — | — | US | disclosed |
| US-20240208955-A1 | SMALL MOLECULE ANTAGONISTS FOR THE RELAXIN-3/RXFP3 SYSTEM | RESEARCH TRIANGLE INSTITUTE | 2024-06-27 | — | — | US | disclosed |
| CN-116963761-A | Small molecule antagonists against relaxin-3/RXFP 3 system | 研究三角协会 | 2023-10-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208955-A1 | SMALL MOLECULE ANTAGONISTS FOR THE RELAXIN-3/RXFP3 SYSTEM | RXFP3, RXFP1, RXFP4 | RXFP3 1/4885TMEM97 1512/4885ALDH1A1 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.